Reducing uncertainty about flavivirus infections

The Lancet Infectious Diseases

Volumn 17, Issue 1, 2017, Pages 13-15

  Kucharski, Adam ^a   Riley, Steven ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTION; DENGUE; DENGUE VIRUS; EPIDEMIC; FLAVIVIRUS INFECTION; HUMAN; IMMUNE RESPONSE; INCIDENCE; NONHUMAN; NOTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SEROLOGY; SEROPREVALENCE; SEROTYPE; ZIKA FEVER; BLOOD; FLAVIVIRUS; IMMUNOLOGY; RISK; UNCERTAINTY; VIROLOGY; ZIKA VIRUS;

VIRUS ANTIBODY;

ANTIBODIES, VIRAL; CROSS REACTIONS; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; RISK; SEROGROUP; UNCERTAINTY; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85008214228     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30524-2     Document Type: Note

References (10)

1. 1 Zanluca, C, Melo, VC, Mosimann, AL, Santos, GI, Santos, CN, Luz, K, First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz 110 (2015), 569–572.
2. 2 Lessler, J, Chaisson, LH, Kucirka, LM, et al. Assessing the global threat from Zika virus. Science, 2016, 10.1126/science.aaf8160 published online July 14.
3. 3 Faria, NR, Azevedo, R do S, Kraemer, MU, et al. Zika virus in the Americas: early epidemiological and genetic findings. Science 352 (2016), 345–349.
4. 4 Makino, Y, Tadano, M, Saito, M, et al. Studies on serological cross-reaction in sequential flavivirus infections. Microbiol Immunol 38 (1994), 951–955.
5. 5 Priyamvada, L, Quicke, KM, Hudson, WH, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA 113 (2016), 7852–7857.
6. 6 Chang, HH, Grad, YH, Camerini, D, Lipsitch, M, Designing serological diagnostics based on evolutionarily divergent immunogenic regions in the Zika virus genome. Bull World Health Organ, 2016, 10.2471/BLT.16.182105 published online July 18.
7. 7 White, MT, Bejon, P, Olotu, A, et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med, 12, 2014, 117.
8. 8 Kucharski, AJ, Lessler, J, Read, JM, et al. Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. PLoS Biol, 13, 2015, e1002082.
9. 9 Salje, H, Cauchemez, S, Alera, MT, et al. Reconstruction of 60 years of chikungunya epidemiology in the Philippines demonstrates episodic and focal transmission. J Infect Dis 213 (2016), 604–610.
10. 10 Reiner, RC Jr, Stoddard, ST, Forshey, BM, et al. Time-varying, serotype-specific force of infection of dengue virus. Proc Natl Acad Sci USA 111 (2014), E2694–E2702.